Skip to main content

Published locations for Ibrutinib holds CLL at bay in majority of patients at 30 months

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Ibrutinib holds CLL at bay in majority of patients at 30 months

User login

  • Reset your password
  • /content/ibrutinib-holds-cll-bay-majority-patients-30-months
  • /hematologynews/article/83148/cll/ibrutinib-holds-cll-bay-majority-patients-30-months
  • /hematology-oncology/article/83148/cll/ibrutinib-holds-cll-bay-majority-patients-30-months
  • /b-cell-lymphoma-icymi/article/83148/cll/ibrutinib-holds-cll-bay-majority-patients-30-months